Stock listing

Dusseldorf:EII Eisai Co., Ltd. Aktie

German listing (Dusseldorf) of Eisai Co., Ltd. · home listing Tokyo:4523

Follow Eisai Co., Ltd. into a list and get an email when it puts out news.

Share price · DUS:EII

€27.97 EUR -1.21 (-4.1%)

Close on Oct 30, 2026

Day range
€27.97 – €28.55 EUROct 30, 2026
Market cap
€15.64B EURAt the close on Oct 30, 2026 · price × 559.1M shares outstanding
Eisai Co., Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
OTC:ESAIY$8.05 USD-0.07 (-0.9%)10,998$8.07$8.07$8.03$8.12Close on Oct 27, 2026
OTC:ESALF$29.97 USD-0.82 (-2.7%)178$29.97$29.97$29.97$30.79Close on Oct 27, 2026
Frankfurt:EII€28.65 EUR-0.70 (-2.4%)—€29.30€29.30€28.65€29.35Close on Oct 27, 2026
Munich:EII€29.18 EUR-0.39 (-1.3%)—€29.18€29.18€29.18€29.57Close on Oct 27, 2026
Dusseldorf:EII€27.97 EUR-1.21 (-4.1%)—€28.16€28.55€27.97€29.18Close on Oct 30, 2026
Ticker
Dusseldorf:EII
Asset type
Stock
Exchange
Dusseldorf
Currency
EUR

What changed lately

Calls

Replays

  • Eisai (Tokyo:4523) Q1 2027 Earnings Call

    Mon, Aug 03, 2026 · 3:00 AM ET

    Watch Transcript

  • Eisai (Tokyo:4523) Q4 2026 Earnings Call

    Fri, May 15, 2026 · 3:00 AM ET

    Watch Transcript

  • Eisai (Tokyo:4523) Q2 2026 Earnings Call

    Fri, Nov 07, 2025 · 2:30 AM ET

    Watch Transcript

Latest news

Revenue of LEQEMBI (Preliminary Basis)

Oct 28, 2026

Notification Regarding Receipt of Dividend from a Consolidated Subsidiary

Oct 2, 2026

U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)

Sep 25, 2026

Leqembi® Pen subcutaneous formulation approved in Japan

Sep 16, 2026

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease

Sep 16, 2026

Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)

Sep 15, 2026

LEQEMBI (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

Sep 3, 2026

CONSOLIDATED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2026

Aug 3, 2026

Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026

Jul 29, 2026

Historic Step for Alzheimer's Care in Canada: CDA-AMC Recognizes Clinical Value of LEQEMBI® (lecanemab) and Recommends Public Coverage for Early Alzheimer's Disease

Jul 16, 2026

All Eisai Co., Ltd. news

Decks

Eisai Co., Ltd. on 6ix

News releases
63 in the last 12 months · 88 in all · newest Oct 28, 2026 · oldest 2025
Calls
8 calls with a replay · 8 with a transcript · latest Aug 3, 2026
Decks
4 decks · latest Aug 3, 2026

Where Eisai Co., Ltd. is listed

ListingExchangeCountryCurrency
Tokyo:4523 エーザイ · Home listingTokyoJapanJPY
OTC:ESAIYOTCUnited StatesUSD
gettex:EIIgettexGermanyEUR
OTC:ESALFOTCUnited StatesUSD
Tradegate:EIITradegateGermanyEUR
LS Exchange:855526LS ExchangeGermanyEUR
Frankfurt:EIIFrankfurtGermanyEUR
Lang & Schwarz:855526Lang & SchwarzGermanyEUR
Hamburg:EIIHamburgGermanyEUR
Hanover:EIIHanoverGermanyEUR
Munich:EIIMunichGermanyEUR
Dusseldorf:EII · This pageDusseldorfGermanyEUR
BIVA:4523NBIVAMexicoMXN
BMV:4523NBMVMexicoMXN
Dusseldorf:EIIADusseldorfGermanyEUR
Frankfurt:EIIAFrankfurtGermanyEUR
Stuttgart:EIIStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Eisai Co., Ltd.